Table 1 Clinical and pathological data of the patients included in this study
(A) IPO Porto’s cohort | ||
Clinicopathological features | MNPT | PCa |
Patients, n | 14 | 100 |
Median age, years (range) | 65 (49–80) | 65 (49–75) |
PSA (ng/mL), median (range) | n.a. | 8.45 (3.5–23) |
pT2 | n.a. | 60 (60%) |
pT3 | n.a. | 40 (40%) |
< 7 | n.a. | 36 (36%) |
= 7 | n.a. | 58 (58%) |
> 7 | n.a. | 6 (6%) |
(B) TCGA’s cohort | ||
Clinicopathological Features | NAT | PCa |
Patients, n | 52 | 497 |
Median age, years (range) | 61 (43–72) | 61 (41–78) |
pT2 | 29 (56%) | 189 (38%) |
pT3 | 21 (40%) | 292 (59%) |
pT4 | 2 (4%) | 10 (2%) |
< 7 | 5 (10%) | 45 (9%) |
= 7 | 40 (77%) | 248 (50%) |
> 7 | 7 (13%) | 204 (41%) |